tiprankstipranks
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Hong Kong Market
2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:2252 full AI Analyst Report?

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Stock Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

2252 Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Shanghai
MicroPort MedBot (Group) Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2252 Stock 12 Month Forecast

Average Price Target

HK$39.27
▲(15.02% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H in the last 3 months. The average price target is HK$39.27 with a high forecast of HK$45.00 and a low forecast of HK$33.00. The average price target represents a 15.02% change from the last price of HK$34.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"HK$14","22":"HK$22","30":"HK$30","38":"HK$38","46":"HK$46"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.26857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$39.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,22,30,38,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.34,26.852307692307694,28.364615384615384,29.876923076923077,31.38923076923077,32.901538461538465,34.41384615384615,35.926153846153845,37.43846153846154,38.95076923076923,40.463076923076926,41.97538461538461,43.48769230769231,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.34,26.411428571428573,27.482857142857142,28.554285714285715,29.625714285714285,30.697142857142858,31.768571428571427,32.84,33.91142857142857,34.98285714285714,36.05428571428571,37.12571428571428,38.19714285714286,{"y":39.26857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.34,25.92923076923077,26.518461538461537,27.107692307692307,27.696923076923078,28.286153846153844,28.875384615384615,29.464615384615385,30.053846153846152,30.643076923076922,31.232307692307693,31.82153846153846,32.41076923076923,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.08,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.3,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.34,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$45.00Average Price TargetHK$39.27Lowest Price TargetHK$33.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guotai Haitong Analyst forecast on HK:2252
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$39.88
Buy
16.81%
Upside
Reiterated
05/27/26
Guotai Haitong Sticks to Their Buy Rating for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
Citi Analyst forecast on HK:2252
Unknown Analyst
Citi
Not Ranked
Citi
HK$41
Buy
20.09%
Upside
Reiterated
05/27/26
Citi Reaffirms Their Buy Rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
Citic Securities Analyst forecast on HK:2252
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$34
Buy
-0.41%
Downside
Reiterated
05/12/26
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Receives a Buy from Citic Securities
Goldman Sachs Analyst forecast on HK:2252
Chris Pan
Goldman Sachs
Goldman Sachs
HK$45
Buy
31.81%
Upside
Initiated
04/21/26
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Initiated with a Buy at Goldman Sachs
J.P. Morgan Analyst forecast on HK:2252
Derek Choi
J.P. Morgan
J.P. Morgan
HK$42
Buy
23.02%
Upside
Reiterated
04/08/26
J.P. Morgan Reaffirms Their Buy Rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
DBS Analyst forecast on HK:2252
Nico Chen
DBS
DBS
HK$33
Buy
-3.34%
Downside
Reiterated
03/30/26
MedBot: Accelerating Overseas Growth and Path to 2026 Breakeven Support Buy Rating
Jefferies Analyst forecast on HK:2252
David Shang
Jefferies
Jefferies
HK$40
Buy
17.16%
Upside
Reiterated
03/30/26
Jefferies Sticks to Its Buy Rating for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
SPDB Analyst forecast on HK:2252
Unknown Analyst
SPDB
Not Ranked
SPDB
HK$23.7
Sell
-30.58%
Downside
Reiterated
09/03/25
UBS Analyst forecast on HK:2252
Unknown Analyst
UBS
Not Ranked
UBS
HK$21.4
Hold
-37.32%
Downside
Reiterated
08/28/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guotai Haitong Analyst forecast on HK:2252
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$39.88
Buy
16.81%
Upside
Reiterated
05/27/26
Guotai Haitong Sticks to Their Buy Rating for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
Citi Analyst forecast on HK:2252
Unknown Analyst
Citi
Not Ranked
Citi
HK$41
Buy
20.09%
Upside
Reiterated
05/27/26
Citi Reaffirms Their Buy Rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
Citic Securities Analyst forecast on HK:2252
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$34
Buy
-0.41%
Downside
Reiterated
05/12/26
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Receives a Buy from Citic Securities
Goldman Sachs Analyst forecast on HK:2252
Chris Pan
Goldman Sachs
Goldman Sachs
HK$45
Buy
31.81%
Upside
Initiated
04/21/26
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Initiated with a Buy at Goldman Sachs
J.P. Morgan Analyst forecast on HK:2252
Derek Choi
J.P. Morgan
J.P. Morgan
HK$42
Buy
23.02%
Upside
Reiterated
04/08/26
J.P. Morgan Reaffirms Their Buy Rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
DBS Analyst forecast on HK:2252
Nico Chen
DBS
DBS
HK$33
Buy
-3.34%
Downside
Reiterated
03/30/26
MedBot: Accelerating Overseas Growth and Path to 2026 Breakeven Support Buy Rating
Jefferies Analyst forecast on HK:2252
David Shang
Jefferies
Jefferies
HK$40
Buy
17.16%
Upside
Reiterated
03/30/26
Jefferies Sticks to Its Buy Rating for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)
SPDB Analyst forecast on HK:2252
Unknown Analyst
SPDB
Not Ranked
SPDB
HK$23.7
Sell
-30.58%
Downside
Reiterated
09/03/25
UBS Analyst forecast on HK:2252
Unknown Analyst
UBS
Not Ranked
UBS
HK$21.4
Hold
-37.32%
Downside
Reiterated
08/28/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shanghai MicroPort MedBot (Group) Co., Ltd. Class H

3 Months
David ShangJefferies
Success Rate
1/4 ratings generated profit
25%
Average Return
+8.38%
Copying David Shang's trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of +8.38% per trade.
1 Year
David ShangJefferies
Success Rate
1/4 ratings generated profit
25%
Average Return
+5.35%
Copying David Shang's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of +5.35% per trade.
2 Years
David ShangJefferies
Success Rate
1/4 ratings generated profit
25%
Average Return
+5.35%
Copying David Shang's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of +5.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2252 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
1
2
3
2
Buy
0
2
3
5
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
3
5
8
5
In the current month, 2252 has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2252 average Analyst price target in the past 3 months is 39.27.
Each month's total comprises the sum of three months' worth of ratings.

2252 Financial Forecast

2252 Earnings Forecast

Next quarter’s earnings estimate for 2252 is -HK$0.01 with a range of -HK$0.01 to -HK$0.01. The previous quarter’s EPS was -HK$0.16. 2252 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2252 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2252 is -HK$0.01 with a range of -HK$0.01 to -HK$0.01. The previous quarter’s EPS was -HK$0.16. 2252 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2252 has Performed in-line its overall industry.

2252 Sales Forecast

Next quarter’s sales forecast for 2252 is HK$512.20M with a range of HK$512.20M to HK$512.20M. The previous quarter’s sales results were HK$410.95M. 2252 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2252 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2252 is HK$512.20M with a range of HK$512.20M to HK$512.20M. The previous quarter’s sales results were HK$410.95M. 2252 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2252 has Performed in-line its overall industry.

2252 Stock Forecast FAQ

What is HK:2252’s average 12-month price target, according to analysts?
Based on analyst ratings, Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s 12-month average price target is 39.27.
    What is HK:2252’s upside potential, based on the analysts’ average price target?
    Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 15.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H a Buy, Sell or Hold?
          Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s share price target?
            The average share price target for Shanghai MicroPort MedBot (Group) Co., Ltd. Class H is 39.27. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$45.00 ,and the lowest forecast is HK$33.00. The average share price target represents 15.02% Increase from the current price of HK$34.14.
              What do analysts say about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
              Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
                To buy shares of HK:2252, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.